<p class="bodytext">A late-stage trial of a Covid-19 candidate vaccine from CanSino Biologics Inc has started in Russia, registration records showed, as the Chinese pharmaceutical firm steps up testing abroad to close in on regulatory approval.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-unlock-30-rules-india-maharashtra-karnataka-delhi-tamil-nadu-mumbai-bengaluru-chennai-ahmedabad-new-delhi-total-cases-deaths-recoveries-today-covid-19-coronavirus-vaccine-covid-vaccine-updates-869265.html">Follow latest updates on the Covid-19 pandemic here</a></strong></p>.<p class="bodytext">The Ad5-nCoV vaccine already has approval for use by China's military after early and mid-stage trials, and further late-stage trials are being lined up for Mexico and Saudi Arabia.</p>.<p class="bodytext">CanSino last month said it was in talks for opportunities to launch late-stage - or Phase 3 - trials in Saudi Arabia, Russia, Brazil and Chile.</p>.<p class="bodytext">The company has won a patent approval from Beijing for the vaccine, Chinese state media reported on Sunday, citing documents from the country's intellectual property regulator.</p>.<p class="bodytext">CanSino and compatriots including Sinovac Biotech Ltd and China National Pharmaceutical Group Co Ltd (Sinopharm) are testing candidates overseas as China becomes less conducive for Phase 3 trials due to its small number of new Covid-19 cases.</p>.<p class="bodytext">The completion of Phase 3 trials is generally required for regulatory approval to distribute a vaccine for public use.</p>.<p class="bodytext">Russia's state register for clinical trials showed a Phase 3 study expected to recruit 625 volunteers across eight medical institutes to test the safety and effectiveness of Ad5-nCoV began on Friday.</p>.<p class="bodytext">CanSino declined to offer more details on the Russian trial when contacted by Reuters, saying the information was confidential.</p>.<p class="bodytext">Russia was the first country to grant regulatory approval for public use of a Covid-19 vaccine, after less than two months of human testing. That vaccine uses adenovirus to carry antigen from coronavirus into human cells, an approach similar to that of Ad5-nCoV.</p>.<p class="bodytext">Last month, Russian biotech group Biocad said it was discussing producing in China a potential Covid-19 vaccine being developed by Russia's Vector state virology institute.</p>.<p class="bodytext">With 927,745 cases, Russia has the world's fourth-highest number of infections.</p>
<p class="bodytext">A late-stage trial of a Covid-19 candidate vaccine from CanSino Biologics Inc has started in Russia, registration records showed, as the Chinese pharmaceutical firm steps up testing abroad to close in on regulatory approval.</p>.<p><strong><a href="https://www.deccanherald.com/national/coronavirus-news-live-updates-unlock-30-rules-india-maharashtra-karnataka-delhi-tamil-nadu-mumbai-bengaluru-chennai-ahmedabad-new-delhi-total-cases-deaths-recoveries-today-covid-19-coronavirus-vaccine-covid-vaccine-updates-869265.html">Follow latest updates on the Covid-19 pandemic here</a></strong></p>.<p class="bodytext">The Ad5-nCoV vaccine already has approval for use by China's military after early and mid-stage trials, and further late-stage trials are being lined up for Mexico and Saudi Arabia.</p>.<p class="bodytext">CanSino last month said it was in talks for opportunities to launch late-stage - or Phase 3 - trials in Saudi Arabia, Russia, Brazil and Chile.</p>.<p class="bodytext">The company has won a patent approval from Beijing for the vaccine, Chinese state media reported on Sunday, citing documents from the country's intellectual property regulator.</p>.<p class="bodytext">CanSino and compatriots including Sinovac Biotech Ltd and China National Pharmaceutical Group Co Ltd (Sinopharm) are testing candidates overseas as China becomes less conducive for Phase 3 trials due to its small number of new Covid-19 cases.</p>.<p class="bodytext">The completion of Phase 3 trials is generally required for regulatory approval to distribute a vaccine for public use.</p>.<p class="bodytext">Russia's state register for clinical trials showed a Phase 3 study expected to recruit 625 volunteers across eight medical institutes to test the safety and effectiveness of Ad5-nCoV began on Friday.</p>.<p class="bodytext">CanSino declined to offer more details on the Russian trial when contacted by Reuters, saying the information was confidential.</p>.<p class="bodytext">Russia was the first country to grant regulatory approval for public use of a Covid-19 vaccine, after less than two months of human testing. That vaccine uses adenovirus to carry antigen from coronavirus into human cells, an approach similar to that of Ad5-nCoV.</p>.<p class="bodytext">Last month, Russian biotech group Biocad said it was discussing producing in China a potential Covid-19 vaccine being developed by Russia's Vector state virology institute.</p>.<p class="bodytext">With 927,745 cases, Russia has the world's fourth-highest number of infections.</p>